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In this issue of Cancer Cell, Ooms and colleagues show that the lipid phosphatase PIPP/INPP5J, frequently
inactivated in triple-negative breast cancers, functions as a tumor suppressor by specifically modulating the
activity of AKT1 in the context of oncogenic PI3K signaling, leading to inhibition of metastatic dissemination.Genes that encode proteins in the phos-
phoinositide 3-kinase (PI3K) and AKT
signaling pathway are frequently mutated
in virtually all human solid and hemato-
logical malignancies. This is particularly
evident in breast cancer, whereby so-
matic oncogenic mutations in the gene
that encodes the p110a catalytic subunit,
PIK3CA, occur with high frequency,
especially in estrogen receptor-positive
(ER+) luminal breast tumors (Fruman and
Rommel, 2014). Similarly, enzymes that
mediate signal termination of PI3K/AKT
signaling are also frequently inactivated.
By definition, these genes function as
tumor suppressors such that their inacti-
vation also leads to hyperactivation of
PI3K/AKT. The best characterized tumor
suppressors in this pathway are the two
lipid phosphatases PTEN and INPP4B
and the serine/threonine phosphatases
PHLPP1/2. Both PTEN and INPP4B cata-
lyze dephosphorylation of PtdIns(3,4,5)P3
(PIP3), the second messenger product of
PI3K that is rate-limiting for AKT activation
(Figure 1). PTEN and INPP4B remove
the 30 and 40 phosphate groups of PIP3,
respectively, whereas PHLPP dephos-
phorylates AKT at Ser473. Inactivation of
any one of these tumor suppressors leads
to excessive PIP3 accumulation and/or
AKT hyperactivation (Gewinner et al.,
2009). In this issue of Cancer Cell, Ooms
et al. (2015) add to the list of genes that
terminate PI3K/AKT signaling by showing
the inositol 50 phosphatase INPP5J, also
referred to as proline rich inositol poly-
phosphate 5-phosphatase (PIPP), is a
tumor suppressor in breast cancer whose
inactivation modulates AKT function.
PIPP dephosphorylates PIP3 under nor-
mal physiological conditions, resulting in
PtdIns(3,4)P2 accumulation, itself a truesecond messenger that promotes AKT
activation. Previous studies had shown
that PIPP opposes oncogenic PI3K
signaling in fibroblasts, but whether PIPP
could function as a tumor suppressor to
modulate AKT function had not been
described. Ooms et al. (2015) now show
that, indeed, depletion of PIPPwith shRNA
in triple negative breast cancer cell lines
enhances proliferation and anchorage in-
dependent growth in vitro and tumor
growth in xenografts in vivo in a manner
that is concomitant with increased AKT
activation. The authors also generated
Pipp knockout mice, which were viable
and displayed no overt phenotypes during
development and with no evidence of
mammary gland abnormalities or initiation
of mammary tumorigenesis. By contrast,
crossing Pipp knockout mice with a
polyoma middle T (PyMT) mammary tu-
mor model resulted in increased mam-
mary hyperplasia and tumor burden in
PyMT;Pipp/ mice, again concomitant
with increased activation of AKT. Consis-
tent with a requirement for PIPP enzymatic
activity, the authors detected increased
PIP3 and decreased PtdIns(3,4)P2 levels
in cells derived from PyMT;Pipp/ tu-
mors. Because the PyMT model faithfully
recapitulates all the stages of mammary
tumorigenesis in a manner that depends
on PI3K, particularly in ER+ tumors, these
data clearly show that PIPP functions as
a bona fide tumor suppressor in the
context of oncogenic PI3K.
Surprisingly, when the authors exam-
ined PyMT;Pipp/ mice for metastatic
lesions, they observed fewer metastases
compared to wild-type littermates, indi-
cating that, while PIPP may contribute to
tumor growth, it functions to attenuate
metastatic dissemination. This observa-Cancer Cell 28tion is reminiscent of findings in trans-
genic mice expressing an activated
AKT1 allele in the mammary epithelium
that display increased primary tumor
growth but a decrease in metastases
(Hutchinson et al., 2004). Subsequent
studies confirmed that AKT1 does indeed
function as a breast cancer invasion and
metastasis suppressor, whereas AKT2
promotes metastatic dissemination (Chin
and Toker, 2009). The Ooms study now
provides evidence for a genetic link be-
tween PIPP and AKT1 as metastasis sup-
pressors. PIPP depletion reduces cell
migration in a manner that depends spe-
cifically on AKT1, but not AKT2. A number
of mechanisms have been shown to
account for the inhibitory effects of AKT1
on invasive migration, including NFAT1
degradation, destabilization of TSC2,
and phosphorylation of the actin bundling
protein palladin. Both PIPP-depleted
cell lines and tumors from PyMT;
Pipp/ mice display decreased NFAT1
and TSC2 protein levels. Therefore,
decreased PIPP expression in the context
of mammary tumorigenesis appears to
attenuate tumor invasion and metastasis
in a manner that is relayed by the activity
of AKT1 (Figure 1B). One question that
remains unanswered is whether the
decrease in PtdIns(3,4)P2 in cells lacking
PIPP contributes to the decreased meta-
static potential of these tumors.
Finally, the authors also found reduced
PIPP and AKT1 mRNA expression in ER
negative (ER–) human tumors compared
toER+ tumors. Interestingly, triple negative
breast cancers, which have many of the
genetic hallmarks of basal-like breast can-
cer but are not necessarily synonymous,
have a relatively lower frequency of onco-
genic PIK3CA mutations compared to, August 10, 2015 ª2015 Elsevier Inc. 143
Figure 1. Differential AKT Signaling in Normal Cells or in Cells Lacking PIPP or PTEN/INPP4B
(A) In normal cells and tissues, PI3K (PIK3CA) catalyzes the conversion of PtdIns(4,5)P2 (PI45P2) into PIP3. The lipid phosphatase PIPP dephosphorylates PIP3 to
generate PtdIns(3,4)P2 (PI34P2) the substrate of INPP4B, thereby generating PtdIns(3)P (PI3P). By contrast, the 3
0 phosphoinositide phosphatase PTEN dephos-
phorylates PIP3 back to the precursor PI45P2. Under these conditions, both AKT1 and AKT2 are activated to a similar extent through binding of PI34P2 and PIP3.
(B) In tumor cells in which PIPP is inactive or suppressed, PIP3 levels are elevated, and AKT1 is the predominantly active isoform that promotes tumorigenesis and
suppression of metastasis.
(C) By contrast, in tumors that lack both PTEN and INPP4B but retain PIPP, AKT2 activity is dominant. This may be due to the accumulation of PI34P2, leading to
tumor growth and enhanced metastatic dissemination.
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Previewsluminal, ER+ breast tumors. Because the
murine PyMT model better recapitulates
luminal breast cancer, it will be interesting
to determine whether loss of PIPP also
contributes to the development of basal-
like breast cancers usingmore defined ge-
netic models of PI3K activation, such as
PTEN or INPP4B loss in the mouse mam-
mary epithelium. Because somatic onco-
genic mutations of AKT1 and AKT2 have
been identified with varying frequencies
in breast cancer patients, it will also be
interesting to assess the contribution of
PIPP in the context of these genetic
lesions.
It remains unclear why AKT1 is the
dominant isoform in the context of144 Cancer Cell 28, August 10, 2015 ª2015 EPIPP depletion. There appears to be no
evidence that PIPP inhibits the activity
of AKT1 over AKT2; rather, the inhibitory
effects of AKT1 on cell migration and
metastasis appear to dominate, at least
in the context of PIPP inactivation.
Nonetheless, these data point to a
model by which the loss of a tumor sup-
pressor, PIPP/INPP5J, mediates breast
cancer progression in an AKT isoform-
specific manner. Remarkably, two very
recent studies arrived at near identical
findings for a related tumor suppres-
sor. INPP4B, which dephosphorylates
PtdIns(3,4)P2 to generate PtdIns(3)P, is
also frequently inactivated in basal-like
breast cancer (Fedele et al., 2010; Ge-lsevier Inc.winner et al., 2009). Loss of INPP4B
leads to activation of AKT, and two
studies by the Pandolfi and Sasaki labo-
ratories showed that, in the context of
PTEN inactivation, INPP4B is indeed a
tumor suppressor and functions exclu-
sively through AKT2 (Kofuji et al., 2015;
Li Chew et al., 2015) (Figure 1C). This
is also consistent with a previous study
that also showed that AKT2 is exclu-
sively required for tumor maintenance
in the setting of PTEN deficiency (Chin
et al., 2014). Collectively, these studies
point to the model that two distinct lipid
phosphatases regulate PI3K/AKT func-
tion by modulating the activation of
specific AKT isoforms: PIPP functioning
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Previewsthrough AKT1 and INPP4B/PTEN func-
tioning through AKT2. Precisely how
this specificity is achieved remains to
be determined, although compartmen-
talization of both the lipid phosphatase
and AKT isoform is likely to play a major
role (Kofuji et al., 2015). It is also
possible that AKT2 is preferentially acti-
vated by local pools of PtdIns(3,4)P2,
such that, when PIPP is absent, less
PtdIns(3,4)P2 is generated and AKT1 be-
comes the dominantly active isoform
(Figure 1B).
There are therapeutic implications for
the finding that AKT1 drives the PIPP
phenotype. Small molecule inhibitors tar-
geting both PI3K and AKT are currently
under clinical evaluation (Fruman and
Rommel, 2014). However, notably, there
are no AKT isoform-selective compounds
that are under development. Although it
remains unclear whether such inhibitors
can be developed with acceptable drug
properties and efficacies, the notion
that AKT isoform-selective activity couldaffect clinical outcome advocates for the
development of such compounds. Also,
although reduced PIPP message levels
are observed in breast cancer and corre-
lated with ER status, because there are
no significant genomic alterations in
PIPP/INPP5J according to TCGA, it is
likely that epigenetic mechanisms ac-
count for the alterations reported by
Ooms et al. (2015). Moreover, because
PIPP is one of ten distinct mammalian 50
lipid phosphatases, future studies that
apply the approaches used to deduce
the tumor suppressor activity of PIPP on
AKT1 function in breast and other solid tu-
mors will likely shed much more light on
the complexities of PI3K and AKT function
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In this issue of Cancer Cell, Herrero and colleagues identify an anti-tumorigenic small molecule that blocks
ERK dimerization, but neither its catalytic activity nor its phosphorylation by MEK. These findings demon-
strate that targeting protein dimerization could be a therapeutic avenue for inhibiting kinase signaling path-
ways associated with lower drug resistance.The ERK/mitogen-activated protein ki-
nase (MAPK) signaling pathway inte-
grates a wide range of signals into major
cellular programs such as proliferation,
differentiation, or apoptosis. Canonical
ERK signaling is initiated upon stimulation
of the small GTPase Ras, which triggers a
sequential three-kinase phosphorylation
cascade through RAF, MEK, and ERK to
enact focused and large-scale cellular
changes. Half of all human malignancies
display aberrations in the Ras-RAF-
MEK-ERK pathway, revealing the extent
of its regulatory reach. To date, prome-thean effort has been expended identi-
fying small molecule inhibitors of this
pathway, because promising compounds
are hampered by significant side effects
and rapid development of drug resistance
(Little et al., 2013).
Sometimes overlooked, kinases are
more than phosphate-transferring en-
zymes. Many exhibit catalytic activity-
independent protein-protein interactions
that are important for context-appro-
priate signal regulation. In addition
to phosphorylating substrates, kinases
serve as binding partners for othersignaling molecules. Indeed, the MAPK
signaling scaffold protein KSR, a RAF
homolog that lacks the catalytic lysine,
tethers RAF, MEK, and ERK and can
induce changes in RAF activity allosteri-
cally (Stewart et al., 1999; Rajakulendran
et al., 2009). Allosteric regulation of ki-
nases is not limited to scaffolds or pseu-
dokinases, because RAF can regulate
itself through dimerization (Lito et al.,
2013). Regulated protein-protein inter-
actions are critical for reducing entropic
barriers to signaling. Although this
makes them tempting for drug design,, August 10, 2015 ª2015 Elsevier Inc. 145
